Molecular PET Imaging and Plasma Biomarkers in Alzheimer´s Disease and Other Neurodegenerative Diseases

Not Applicable

• Conditions: Alzheimer´s Disease

• Registration Number: NCT06731842
• Lead Sponsor: Karolinska Institutet

Brief Summary

Multi-modal PET tracer study with the aim of studying the time course of regional deposition of tau in brain of subjects with high risk of being carriers of autosomal dominant Alzheimer´s disease and sporadic early onset and late onset Alzheimer´s disease patient (EOAD, LOAD) in tertiary memory clinic cohort in relation to MRI brain changes, plasma biomarker levels and cognitive performance.

Detailed Description

Multi-PET /MRI studies , fluid biomarkers (CSF, plasma) analysis, neuropsychological testing is performed in subjects carriers and non-carriers of different APP, PS autosomal dominant AD mutatation. Both presymptomatic and symptomatic carriers and non-carriers are recruited (age range -30 to +15 years from first clinical symptoms). For comparison also a group of healthy eldersly as well as patients undergoing memory assessment with diagnosis of mild cognitive impairment (amyloid negative /amyloid positive) and diagnosis sporadic Alzheimer´s diases are recruited from Karolinska memory clinic and undergoing similar Multi-PET/MRI studies , fluid biomarker analysis, neuropsycholigal testing. The aim is to describe the evolution and spreading of tau in brain in Alzheimer continuum and compare with other pathological markers with aim of develop new diagnostic markers and therapeutic targets.

Study Timeline

• Study Start: 2022-05-15
• Status Verified: 2024-09
• Study First Submitted: 2024-12-09
• Study First Submitted QC: 2024-12-09
• Last Update Submitted: 2024-12-09
• Study First Posted: 2024-12-12
• Last Update Posted: 2024-12-12
• Primary Completion: 2027-12-31
• Study Completion: 2027-12-31

Recruitment & Eligibility

• Status: ENROLLING_BY_INVITATION
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

a)belonging to families with known familial form of Alzheimer´s disease b) patient undergoing memory assessent at memory clinic with diagnosis mild cognitive impairment (MCI), Alzheimer´s disease c)healthy elderly cognitive normal

Exclusion Criteria

cancer and other serious disease

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
PET measurement of regional tau spreading in brain during Alzheimer continuum	3 years	Anaysis of regional deposition of tau in brain

Trial Locations

Locations (1)

Karolinska institutet NVS; 🇸🇪 Stockholm, Sweden